Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Up 38.0% in January

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 52,250 shares, a growth of 38.0% from the December 31st total of 37,856 shares. Based on an average daily trading volume, of 41,827 shares, the short-interest ratio is presently 1.2 days. Approximately 2.7% of the company’s stock are short sold. Approximately 2.7% of the company’s stock are short sold. Based on an average daily trading volume, of 41,827 shares, the short-interest ratio is presently 1.2 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Alaunos Therapeutics in a research note on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Alaunos Therapeutics Stock Down 4.4%

TCRT stock traded down $0.12 during mid-day trading on Friday, reaching $2.63. 37,662 shares of the stock traded hands, compared to its average volume of 27,148. The firm has a market capitalization of $6.10 million, a PE ratio of -1.14 and a beta of -1.28. The business has a 50-day moving average of $3.36 and a two-hundred day moving average of $2.91. Alaunos Therapeutics has a 52 week low of $1.31 and a 52 week high of $6.20.

Alaunos Therapeutics (NASDAQ:TCRT) last announced its earnings results on Friday, November 14th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($4.90) by $4.35.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.